174 180

Cited 3 times in

Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension.

Authors
 Mi-Seung Shin  ;  Dae Ryong Kang  ;  Changsoo Kim  ;  Eun Joo Cho  ;  Ki-Chul Sung  ;  Seok-Min Kang  ;  Dong-Soo Kim  ;  Seung Jae Joo  ;  Seung Hwan Lee  ;  Kyung-Kuk Hwang  ;  Jeong Bae Park 
Citation
 DRUG DESIGN DEVELOPMENT AND THERAPY, Vol.10 : 1573-1580, 2016 
Journal Title
 DRUG DESIGN DEVELOPMENT AND THERAPY 
Issue Date
2016
MeSH
Angiotensin Receptor Antagonists/chemistry ; Angiotensin Receptor Antagonists/therapeutic use* ; Antihypertensive Agents/therapeutic use* ; Biphenyl Compounds/chemistry ; Biphenyl Compounds/pharmacology* ; Blood Pressure/drug effects* ; Humans ; Hypertension/drug therapy* ; Pyrimidines/chemistry ; Pyrimidines/pharmacology* ; Tetrazoles/chemistry ; Tetrazoles/pharmacology*
Keywords
angiotensin receptor blockers ; blood pressure variability ; hypertension
Abstract
BACKGROUND: The angiotensin receptor antagonist fimasartan lowered blood pressure (BP) in a previous large population study. The purpose of this study was to evaluate whether fimasartan treatment for 3 months affects clinical and home BP variability in addition to reducing BP. METHODS: The study enrolled 1,396 patients (mean age 56.2±10.0 years; males 53.6%) with mild-to-moderate hypertension who had a complete set of home BP measurements (morning and evening) and metabolic risk evaluation. During the 3 months of study, fimasartan alone was used to control BP at a daily dose of 30-120 mg. Clinical and home BP measurements were performed before and after the 3-month treatment. BP variability included beat-to-beat variability (clinical) and day-to-day variability (home). RESULTS: Fimasartan reduced BP after 3 months of treatment. The average reduction of clinical systolic BP (c-SBP) was 15.08±18.36 mmHg (P<0.0001), and the average reduction of morning home SBP (m-SBP) was 11.49±19.33 mmHg (P<0.0001). Beat-to-beat variability as standard deviation (SD) of c-SBP was reduced from 4.56±3.22 to 4.24±3.11 mmHg (P=0.0026). Day-to-day variability as SD of m-SBP was reduced from 7.92±6.74 to 6.95±4.97 mmHg (P<0.0001). Multiple regression analysis revealed an independent association between the change in the SD of c-SBP and the change in c-SBP (P=0.0268) and, similarly, between the change in the SD of m-SBP and the change in m-SBP (P=0.0258), after adjusting for age, sex, body mass index, and change in mean BP. CONCLUSION: This study indicated that 3 months of fimasartan treatment reduced day-to-day BP variability independent of BP reduction in patients with hypertension.
Files in This Item:
T201601748.pdf Download
DOI
10.2147/DDDT.S107433
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine and Public Health (예방의학교실) > 1. Journal Papers
Yonsei Authors
Kang, Seok Min(강석민) ORCID logo https://orcid.org/0000-0001-9856-9227
Kim, Chang Soo(김창수) ORCID logo https://orcid.org/0000-0002-5940-5649
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/146931
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse